Yorvipath Injection, Solution
NDC Package 73362-101-01

View Billable Units, 11-Digit Conversion Format, and RxNorm mappings
Table of Contents
    1. Package Information
    2. Frequently Asked Questions

Package Information

Yorvipath (palopegteriparatide) injection is yORVIPATH is indicated for the treatment of hypoparathyroidism in adults. This formulation utilizes a injection, solution delivery system. Marketed by Ascendis Pharma, Endocrinology, Inc., this product is identified by NDC 73362-101 and is authorized under FDA application NDA216490.

Identification & Billing

NDC Package Code
73362-101-01
Package Description
2 BOX in 1 CARTON / 1 SYRINGE in 1 BOX (73362-101-02) / 1 CARTRIDGE in 1 SYRINGE (73362-101-03) / .98 mL in 1 CARTRIDGE
Product Code
73362-101
11-Digit Billing Format
73362010101
Billing Unit
ML - Billing unit of "milliliter" is used when a product is measured by its liquid volume.
RxNorm Crosswalk
  • RxCUI: 2693637 - palopegteriparatide 168 MCG in 0.56 ML Pen Injector
  • RxCUI: 2693637 - 0.56 ML teriparatide 0.3 MG/ML Pen Injector
  • RxCUI: 2693637 - teriparatide 168 MCG (equivalent to palopegteriparatide 1935 MCG) per 0.56 ML Pen Injector
  • RxCUI: 2693643 - Yorvipath 168 MCG in 0.56 ML Pen Injector
  • RxCUI: 2693643 - 0.56 ML teriparatide 0.3 MG/ML Pen Injector [Yorvipath]

Clinical Specifications

Proprietary Name
Yorvipath
Non-Proprietary Name
Palopegteriparatide
Substance Name
Palopegteriparatide
Dosage Form
Injection, Solution - A liquid preparation containing one or more drug substances dissolved in a suitable solvent or mixture of mutually miscible solvents that is suitable for injection.
Administration Route
Subcutaneous - Administration beneath the skin; hypodermic. Synonymous with the term SUBDERMAL.
Active Ingredient(s)
PALOPEGTERIPARATIDE 294 ug/.98mL
Pharmacologic Class
Usage Information
YORVIPATH is indicated for the treatment of hypoparathyroidism in adults.

Regulatory & Marketing

Labeler Name
Ascendis Pharma, Endocrinology, Inc.
Product Type
Human Prescription Drug
FDA Application #
NDA216490
Marketing Category
NDA - A product marketed under an approved New Drug Application.
Start Marketing Date
08-09-2024
Listing Expiration
12-31-2027
Exclude Flag
N
Sample Package
No

Hierarchy Structure

Code Lineage

The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.

* Please review the full disclaimer at the bottom of this page.

Frequently Asked Questions

What is the distribution configuration for this product package?

The code 73362-101-01 identifies a specific commercial package of 2 box in 1 carton / 1 syringe in 1 box (73362-101-02) / 1 cartridge in 1 syringe (73362-101-03) / .98 ml in 1 cartridge of Yorvipath, a human prescription drug labeled by Ascendis Pharma, Endocrinology, Inc.. This injection, solution is formulated for subcutaneous use and contains palopegteriparatide as the active substance.

Is this product currently listed with the FDA?

Yes, this product is active and verified within the NDC Directory. It was introduced to the market by Ascendis Pharma, Endocrinology, Inc. on August 09, 2024. The current certification is valid through December 31, 2027.

How is this Ascendis Pharma, Endocrinology, Inc. product billed for insurance claims?

For medical billing and reimbursement, this package follows the 11-digit CMS format: 73362010101. Quantities are measured in per "ml or milliliter", products billed per milliliter are usually products measured by liquid volume.. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.

11-Digit Code Conversion

Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:

10-Digit Format (5-3-2)
73362-101-01
11-Digit CMS (5-4-2)
73362-0101-01

Note: The zero is added to the Product segment to maintain the 5-4-2 structure.